In January–June 2023, Russian manufacturers produced 342.5 billion rubles’ worth of ready-made pharmaceutical drugs (manufacturer’s prices, VAT included), down 2.6% from the same period in 2022.
The Russian pharmaceutical company NovaMedica has announced the production and market launch of the first large batch of the drug Relonova® intended for relief of migraine-associated headaches.
In January–May 2023, Russian manufacturers produced 282 billion rubles’ of pharmaceutical drugs (manufacturer’s prices, VAT included), down 5.8% from the same period in 2022.
In January–March 2023, the online sales or reservations of pharmacy products (pharmaceutical drugs and parapharmaceuticals) in Russia were 80.2 billion rubles (end-user prices, VAT included), up 2.3% from January–March 2022 (against 69.6% in Q1 2022, with its rush demand).
On June 16, GEROPHARM and the Government of Saint Petersburg at SPIEF-2023 signed a cooperation agreement to implement the investment project aimed at expanding the manufacture of medicinal products and increasing their export potential.